A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.

Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. J Cancer Res Clin Oncol (2014) 0.96

Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Invest New Drugs (2015) 0.88

Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer. Angiogenesis (2015) 0.84

Sequencing the head and neck cancer genome: implications for therapy. Ann N Y Acad Sci (2014) 0.83

mTOR pathway: A current, up-to-date mini-review (Review). Oncol Lett (2014) 0.81

Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol (2015) 0.81

Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC). Cancers (Basel) (2016) 0.81

Combination therapy with bevacizumab and temsirolimus in squamous cell carcinoma of the head and neck. Oral Oncol (2013) 0.75

Effect of Momordica charantia protein on proliferation, apoptosis and the AKT signal transduction pathway in the human endometrial carcinoma Ishikawa H cell line in vitro. Oncol Lett (2017) 0.75

Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma. Int J Mol Sci (2017) 0.75

Current understanding of the tumor microenvironment of laryngeal dysplasia and progression to invasive cancer. Curr Opin Otolaryngol Head Neck Surg (2016) 0.75

Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group. Br J Clin Pharmacol (2016) 0.75

Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma. Oncotarget (2017) 0.75

CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab. J Transl Med (2015) 0.75

Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28

Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol (2006) 20.28

The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88

Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10

Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med (2008) 11.86

Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12

Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33

Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol (2008) 7.97

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther (2011) 4.22

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene (2008) 4.13

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol (2004) 3.67

Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res (1993) 3.62

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol (2006) 3.35

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene (2003) 3.32

AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem (2003) 2.88

A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn (2010) 2.86

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol (2003) 2.85

Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res (2007) 2.21

Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer (2008) 2.03

PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res (2006) 1.90

Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res (2004) 1.83

Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol (2004) 1.46

Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer (2003) 1.44

Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer (2008) 1.29

Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer (2007) 1.22

Immune suppression in head and neck cancers: a review. Clin Dev Immunol (2011) 1.17

Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients. Laryngoscope (2002) 1.15

Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol (2009) 1.12

Epidermal growth factor receptor is essential for Toll-like receptor 3 signaling. Sci Signal (2012) 1.12

Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature. Transplantation (2012) 1.06

Creating oral squamous cancer cells: a cellular model of oral-esophageal carcinogenesis. Proc Natl Acad Sci U S A (2005) 1.05

Prevalence of secondary lymphedema in patients with head and neck cancer. J Pain Symptom Manage (2011) 1.03

Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther (2010) 1.03

Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. Cancer (2010) 1.00

A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer (1983) 0.98

Strong immunohistochemical expression of vascular endothelial growth factor predicts overall survival in head and neck squamous cell carcinoma. Ann Surg Oncol (2007) 0.94

Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol (2012) 0.94

PTEN expression and methylation status in oral squamous cell carcinoma. Oncol Rep (2008) 0.91

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179). Ann Oncol (2011) 0.87

mTOR regulates T-cell differentiation and activation in immunity and autoimmunity. Crit Rev Eukaryot Gene Expr (2011) 0.84

A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). Cancer Chemother Pharmacol (2012) 0.83

A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78

Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med (2010) 22.74

The B73 maize genome: complexity, diversity, and dynamics. Science (2009) 18.73

The accessible chromatin landscape of the human genome. Nature (2012) 16.86

Systematic localization of common disease-associated variation in regulatory DNA. Science (2012) 14.47

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29

Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36

An expansive human regulatory lexicon encoded in transcription factor footprints. Nature (2012) 7.27

The genome of a songbird. Nature (2010) 5.90

The genome of woodland strawberry (Fragaria vesca). Nat Genet (2010) 5.86

Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol (2003) 4.44

Global regulation of erythroid gene expression by transcription factor GATA-1. Blood (2004) 4.22

Assemblathon 2: evaluating de novo methods of genome assembly in three vertebrate species. Gigascience (2013) 4.11

LTR_FINDER: an efficient tool for the prediction of full-length LTR retrotransposons. Nucleic Acids Res (2007) 3.89

Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol (2003) 3.27

Reference genome sequence of the model plant Setaria. Nat Biotechnol (2012) 3.21

Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol (2005) 3.12

Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol (2012) 3.04

De novo genome sequencing and comparative genomics of date palm (Phoenix dactylifera). Nat Biotechnol (2011) 2.94

A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn (2010) 2.86

A temporal chromatin signature in human embryonic stem cells identifies regulators of cardiac development. Cell (2012) 2.81

Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res (2013) 2.81

Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer (2013) 2.69

The genome of the pear (Pyrus bretschneideri Rehd.). Genome Res (2012) 2.55

Diaqua-bis(5-carb-oxy-2-propyl-1H-imidazole-4-carboxyl-ato-κN,O)manganese(II) N,N-dimethyl-formamide disolvate. Acta Crystallogr Sect E Struct Rep Online (2009) 2.35

Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn (2009) 2.35

Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg (2009) 2.31

Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes Chromosomes Cancer (2008) 2.29

Low expression of microRNA-126 is associated with poor prognosis in colorectal cancer. Genes Chromosomes Cancer (2014) 2.24

Dose-finding with two agents in Phase I oncology trials. Biometrics (2003) 2.23

Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest (2007) 2.19

Endometrial regenerative cells: a novel stem cell population. J Transl Med (2007) 2.19

Antagonistic HLH/bHLH transcription factors mediate brassinosteroid regulation of cell elongation and plant development in rice and Arabidopsis. Plant Cell (2009) 2.17

Ultrasound-guided peripheral intravenous access in the emergency department using a modified Seldinger technique. J Emerg Med (2009) 2.08

Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res (2006) 2.05

Defibrillation delivered during the upstroke phase of manual chest compression improves shock success. Crit Care Med (2010) 2.04

Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res (2012) 2.02

catena-Poly[[diaqua-(1,10-phenanthroline-κN,N')nickel(II)]-μ-1H-benzimidazole-5,6-dicarboxyl-ato-κN:O]. Acta Crystallogr Sect E Struct Rep Online (2009) 1.99

Prospective evaluation of household contacts of persons with hantavirus cardiopulmonary syndrome in chile. J Infect Dis (2007) 1.97

Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol (2008) 1.95

Techniques for teaching electrocardiogram interpretation: self-directed learning is less effective than a workshop or lecture. Med Educ (2011) 1.95

Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis (2004) 1.92

Penta-aqua-(1H-benzimidazole-5,6-di-carboxyl-ato-κN)cobalt(II) penta-hydrate. Acta Crystallogr Sect E Struct Rep Online (2009) 1.92

Three-dimensional nanostructured substrates toward efficient capture of circulating tumor cells. Angew Chem Int Ed Engl (2009) 1.86

Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression. Proc Natl Acad Sci U S A (2007) 1.81

Restoring methicillin-resistant Staphylococcus aureus susceptibility to β-lactam antibiotics. Sci Transl Med (2012) 1.80

Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One (2011) 1.78

BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore) (2012) 1.77

Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One (2010) 1.77

Breastfeeding of newborns by mothers carrying hepatitis B virus: a meta-analysis and systematic review. Arch Pediatr Adolesc Med (2011) 1.76

Global view of the functional molecular organization of the avian cerebrum: mirror images and functional columns. J Comp Neurol (2013) 1.76

New best1 mutations in autosomal recessive bestrophinopathy. Retina (2015) 1.75

Effectiveness of adjuvant chemotherapy for node-positive operable breast cancer in older women. J Gerontol A Biol Sci Med Sci (2005) 1.73

Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer (2003) 1.73

Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer (2006) 1.72

Widespread site-dependent buffering of human regulatory polymorphism. PLoS Genet (2012) 1.72

Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest (2009) 1.68

Blood leukocyte DNA hypomethylation and gastric cancer risk in a high-risk Polish population. Int J Cancer (2010) 1.67

Relation of low vitamin D to nonvalvular persistent atrial fibrillation in Chinese patients. Ann Noninvasive Electrocardiol (2013) 1.66

Response of intracranial metastases to erlotinib therapy. J Clin Oncol (2007) 1.66

Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res (2005) 1.64

Compound prioritization methods increase rates of chemical probe discovery in model organisms. Chem Biol (2011) 1.64

GPR30 predicts poor survival for ovarian cancer. Gynecol Oncol (2009) 1.63

Genetic evidence linking SAP, the X-linked lymphoproliferative gene product, to Src-related kinase FynT in T(H)2 cytokine regulation. Immunity (2004) 1.63

Human papillomavirus-related carcinomas of the sinonasal tract. Am J Surg Pathol (2013) 1.63

Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. J Transl Med (2009) 1.62

Protein kinase C and A sites on troponin I regulate myofilament Ca2+ sensitivity and ATPase activity in the mouse myocardium. J Physiol (2003) 1.62

The value of a complete blood count in predicting cancer of the colon. Cancer Detect Prev (2004) 1.61

Obesity and restless legs syndrome in men and women. Neurology (2009) 1.61

Interstrand DNA cross-links induced by alpha,beta-unsaturated aldehydes derived from lipid peroxidation and environmental sources. Acc Chem Res (2008) 1.60

Management of acquired bronchobiliary fistula: A systematic literature review of 68 cases published in 30 years. World J Gastroenterol (2011) 1.59

Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain. Pain (2010) 1.59

Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer (2006) 1.59

Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest (2015) 1.54

Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res (2004) 1.53

Axon guidance by diffusible chemoattractants: a gradient of netrin protein in the developing spinal cord. J Neurosci (2006) 1.51

Postresuscitation myocardial diastolic dysfunction following prolonged ventricular fibrillation and cardiopulmonary resuscitation. Crit Care Med (2008) 1.51

Differentiation of HIV-associated lymphoma from HIV-associated reactive adenopathy using quantitative FDG PET and symmetry. Eur J Nucl Med Mol Imaging (2014) 1.51

Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer (2007) 1.50

Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation. Proc Natl Acad Sci U S A (2013) 1.49

Risk factors for early postoperative complications after pneumonectomy for benign lung disease. Ann Thorac Surg (2013) 1.49

Predicting malignancy in mediastinal lymph nodes by endobronchial ultrasound: a new ultrasound scoring system. Respirology (2012) 1.47

A straightforward and highly efficient precipitation/on-pellet digestion procedure coupled with a long gradient nano-LC separation and Orbitrap mass spectrometry for label-free expression profiling of the swine heart mitochondrial proteome. J Proteome Res (2009) 1.46

Diaqua-bis(5-carb-oxy-2-propyl-1H-imidazole-4-carboxyl-ato-κN,O)nickel(II) N,N-dimethyl-formamide disolvate. Acta Crystallogr Sect E Struct Rep Online (2010) 1.45

Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation (2010) 1.45

Longitudinal predictors of continued tobacco use among patients diagnosed with cancer. Ann Behav Med (2003) 1.45

Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression. Mol Cancer (2006) 1.44

Association of a variant in MIR 196A2 with susceptibility to hepatocellular carcinoma in male Chinese patients with chronic hepatitis B virus infection. Hum Immunol (2010) 1.43

Comparative shotgun proteomics using spectral count data and quasi-likelihood modeling. J Proteome Res (2010) 1.43

Individual effect of components of defibrillation waveform on the contractile function and intracellular calcium dynamics of cardiomyocytes. Crit Care Med (2009) 1.43

A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle. Cancer Res (2009) 1.43

G protein activation without a GEF in the plant kingdom. PLoS Genet (2012) 1.43

Stereoselectivity of satropane, a novel tropane analog, on iris muscarinic receptor activation and intraocular hypotension. Acta Pharmacol Sin (2008) 1.42

Matrix metalloprotease 9 promotes liver recovery from ischemia and reperfusion injury. J Surg Res (2012) 1.41

Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol (2010) 1.40

Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial. Crit Care Med (2007) 1.40

High-performance III-V MOSFET with nano-stacked high-k gate dielectric and 3D fin-shaped structure. Nanoscale Res Lett (2012) 1.40

DNase I-hypersensitive exons colocalize with promoters and distal regulatory elements. Nat Genet (2013) 1.40